IDegLira (NN9068)

:Type 2 diabetes
:Phase 3

A fixed-ratio combination of insulin degludec and liraglutide intended to offer the benefits of the two components in a single preparation.

Company announcements
The final phase 3a trial for IDegLira completed, and FIAsp approved for phase 3 development (19 Dec 2012)
Novo Nordisk increased operating profit by 31% in the first half of 2012 (09 Aug 2012)
Read more company announcements

Press releases
No press releases matching the search criteria
 

Scientific abstracts

No scientific abstracts matching the search criteria


You can search for more clinical trials on http://clinicaltrials.gov
  •